Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Equillium Inc

EQ
Current price
0.44 USD -0.032 USD (-6.77%)
Last closed 0.48 USD
ISIN US29446K1060
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 16 788 070 USD
Yield for 12 month -73.12 %
1Y
3Y
5Y
10Y
15Y
EQ
21.11.2021 - 28.11.2021

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody, which is in phase 3 clinical trial to treat acute graft-versus-host disease, as well as completed Phase 1b clinical trial to treat systemic lupus erythematosus and lupus nephritis and in phase 2 clinical trial for the treatment of ulcerative colitis. The company also develops EQ101, first-in-class, selective, tri-specific inhibitor of IL-2, IL-9 and IL-15, which completed Phase 1/2 to treat cutaneous T cell lymphoma. It serves its products to gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology areas. The company has a collaboration and license agreement with Biocon SA to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise exploit itolizumab (EQ001) and any pharmaceutical composition or preparation containing or comprising itolizumab (EQ001) that uses Biocon technology or Biocon know-how, or collectively, a Biocon Product. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.00 USD

P/E ratio

Dividend Yield

Current Year

+41 095 000 USD

Last Year

+36 084 000 USD

Current Quarter

+4 392 000 USD

Last Quarter

+12 161 000 USD

Current Year

+41 095 000 USD

Last Year

+35 958 000 USD

Current Quarter

+4 392 000 USD

Last Quarter

+12 161 000 USD

Key Figures EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -8 132 000 USD
Operating Margin TTM -106.97 %
Price to Earnings
Return On Assets TTM -13.58 %
PEG Ratio
Return On Equity TTM -38.75 %
Wall Street Target Price 1.00 USD
Revenue TTM 41 095 000 USD
Book Value 0.54 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -52.30 %
Dividend Yield
Gross Profit TTM 41 095 000 USD
Earnings per share -0.23 USD
Diluted Eps TTM -0.23 USD
Most Recent Quarter IV 2024
Quarterly Earnings Growth YOY
Profit Margin -19.63 %

Dividend Analytics EQ

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
Dividend CAGR 3Y
Dividend CAGR 5Y
Dividend CAGR 10Y
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
Forward Annual Dividend – USD
Last Split Factor
Payout Ratio TTM
Last Split Date

Stock Valuation EQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 1.53
Enterprise Value Revenue 0.062
Price Sales TTM 0.41
Enterprise Value EBITDA 0.067
Price Book MRQ 0.90

Financials EQ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators EQ

For 52 weeks

0.36 USD 1.89 USD
50 Day MA 0.67 USD
Shares Short Prior Month 363 002
200 Day MA 0.78 USD
Short Ratio 2.08
Shares Short 283 162
Short Percent 1.29 %